Thank you Katerina, and welcome from my part also.
This is now, as Katerina said, the first quarter we report with the new revenue recognition principles. And we believe that this new reporting will improve the transparency of our financial reporting and the understanding of our business logic.
We have looked at and judged the distribution customer contracts and reclassified Oriola as an agent in these contracts. This has had an impact on net sales, and we will now be recognizing net sales on a net basis. So this is the only change in the pharmaceutical company contracts that we have. It's not a change to our own business. So, not all contracts have been reclassified.
This has, of course, had an impact on the segments due to this.
And we now have the two segments that Katerina mentioned: the Services segment, which is based on a service fee, and the Products segment, where there is no change in revenue recognition.
If we then look at the segments, the Services segment is distribution of pharmaceuticals. We are distributing about 300 million packs per year.
We have 4 billion in invoicing that we perform as a service to the pharmaceutical companies. This segment also, of course, includes services that we do to these same companies. And then we have parallel import and advisory services are included.
So it's a big invoicing, but now the net sales have declined.
That is more related to the service fee that we invoice.
So it's a huge pass-through margin.
And, with net sales being smaller, the Product segment is where we have the ownership of the products.
The risk is in our hands, and we have the products in our own inventory also. The product segment, in a big picture, includes the wholesale and the dose dispensing business in Finland.
The product segment also includes now for Q1 2025. It includes the Swedish Dose Dispensing business. We have tried to open that up also in the different tables and comments so that it's clear what is what.
Then, if we go to the numbers, invoicing grew by 8.1% from 1 billion. This is then mainly the pass-through where we invoice on behalf of the customers. We had a decline in net sales.
This is mainly due to the fact that we had the Swedish dose dispensing business in the first quarter last year. If we exclude that, we have a growth of10.7%. There is an FX impact of the Swedish krona that has strengthened during the same time. So approximately two percentage points of the 10.7% is affected by the FX. Svensk dos AB was only included in the first quarter last year.
It was sold on the 1st of April. If you look at the development on net sales, we can say that it's coming both from the Services and Products segments. Especially the distribution services have been performing well both in Finland and Sweden. And we have a good growth in wholesale and also in the dose dispensing. There is also good growth in the dose dispensing business and in parallel import.
Then if we look at the adjusted EBITDA, we have an improvement from 7.5 million to 7.7 million. It's mainly driven by the product segment. We have an adjusted EBITDA margin of 15.4% compared to 14.8%. If we exclude the dose dispensing business in Sweden, it's slightly declining. This is mainly due to the impact by the parallel import and the slow start for the advisory business.
In the adjusting items, we have 2.4 million, a bit more than last year. It was 1.6 million last year. And that is related to the ERP project.
As Katerina said, we have a very small impact from, for example, fuel price increases and costs for the quarter.
And Järvenpää. Just a reminder that we have started to build in Järvenpää. And those costs are not shown as a lease agreement. So we are not having those costs before we move into the facilities or start producing or delivering there.
Then if you go to the services segment.
Good growth in distribution, specialty flows, and parallel import; advisory services. Slow and declining slightly. And we can see that the invoicing is growing 8.5%, net sales growing only 3.7%, on top of the slow start of the advisory services. It's good to remember that we have pricing that also affects why it doesn't always follow the invoicing. We have margin-based and transaction-based pricing towards the customers, which will, of course, have an impact on the development of the net sales in comparison to the invoicing. If we look at the adjusted EBITDA, it is slightly declining.
And that is mainly affected by the decline in net sales from advisory services and in the EBITDA percentage. The parallel import also has an impact due to the fact that it's not as profitable as the other services. If we go to the product segment. This has been performing well. Overall. Both the wholesale and and the dose dispensing business in Finland has been performing both very well. This is then where we have the ownership of the products we source and sell.
We can see that net sales are declining. That's related again to the Swedish dose dispensing business.
So, 9.6% was the growth without the dose dispensing business. EBITDA grew from 1 million to 2.1 million. The EBITDA margin is now at 13.9%.
So we are starting to come up to the right level in a way that it should be in this product business.
Then if we look at the development of the result all the way down to the net profit, EBITDA was slightly lower than last year, mainly related to the adjusting the cost for the ERP and the adjusting items. If we look at the depreciations, we had a Svensk dos AB impairment last year, which increased the impairment. The impairment was 8.8. This year, we have now accelerated the depreciations of some Mankkaa assets and will have some more depreciations until we move to Järvenpää. Looking at the EBIT improving from last year, and of course, the share of result in the joint venture was a disappointment, -2.3 million, and we ended up in a profit for the period of -2 million.
Then if we look at the cash flow, the free cash flow was negative. This is mainly related to the change in the working capital. We have really large payments coming in, and we had a few payments coming in a day or two days late, which affected the. The negative change in working capital of 20 million.
The investment of 5.4 million is mainly related to the. To the acquisition of the land area in Järvenpää. And that's the only part that is affecting us. We bought the land ourselves for the facilities there.
Net debt.
No big change. Slightly impacted by the working capital and the free cash flow. No more comments on that.
Then we have the equity ratio and gearing; the equity ratio was impacted slightly, mainly by the negative impact on the adjusting items again. And the result from the JV, and we can see that the gearing was also impacted by the negative cash flow. And then if you look at this, it was a weak quarter for Kronans, a disappointment for us regarding profit. All lines are lower than 2025. Most important, they are now starting an initiative to focus on growth and cost cutting, and that, in the plan, will improve the profitability starting already from quarter two onwards. And the outlook is the same. We expect the adjusted EBITDA to increase from the previous year. And the previous year was 35.1 million. So that was unchanged from last time.
And then we also communicated the new financial targets. Both of these are, of course. Set to drive profitability. First, we need to grow.
We have set a target to grow at least 5%. We know that we are growing more right now, but we also know that over time, this growth has not always been sustained.
So, if in our strategy, we are aiming at 5% at least, then we have the efficiency target: adjusted cost to net sales.
This is a driver to improve on EBITDA. We need to manage our cost base and see that we get the pass-through margin from the growth that we have. We have also now put it at 75%. Last year, we were at 82.6%. And now for the first quarter, we are at 85.2%. The first quarter does not fully reflect the full year, but there is also a timing issue. But we have improved from 2024 to 2025. We have also improved now quarter on quarter from 2025 to 2026.
Then we have also a new dividend policy, partly new, partly old. We do not change the two-thirds of the net profit. What we have included is that the result from the JV is excluded. And then, of course, there's a disclaimer to evaluate the financial status or situation when dividends are paid.
Then there was a decision by the board to initiate a share buyback program.
Will now be initiated. Now, a maximum of 1 million shares and a maximum of 1.5 million are to be used. Thank you Max.